Andrew Hartley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1844040/publications.pdf

Version: 2024-02-01

28 papers	1,270 citations	840585 11 h-index	642610 23 g-index
28 all docs	28 docs citations	28 times ranked	2203 citing authors

#	Article	IF	Citations
1	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet, The, 2019, 393, 51-60.	6.3	697
2	Cancer of the anal canal. Lancet Oncology, The, 2004, 5, 149-157.	5.1	172
3	A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epsteinâ€“Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer. Clinical Cancer Research, 2014, 20, 5009-5022.	3.2	139
4	Geographic variation in human papillomavirusâ€“related oropharyngeal cancer: Data from 4 multinational randomized trials. Head and Neck, 2016, 38, E1863-9.	0.9	41
5	Hypofractionated Accelerated Radiotherapy With Concurrent Chemotherapy For Locally Advanced Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1342-1351.	0.4	33
6	The Expanding Role of Radiosurgery for Brain Metastases. Medicines (Basel, Switzerland), 2018, 5, 90.	0.7	32
7	Radiobiological Modelling of the Therapeutic Ratio for the Addition of Synchronous Chemotherapy to Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Oncology, 2010, 22, 125-130.	0.6	30
8	Revising the Radiobiological Model of Synchronous Chemotherapy in Head-and-Neck Cancer: A New Analysis Examining Reduced Weighting of Accelerated Repopulation. International Journal of Radiation Oncology Biology Physics, 2013, 86, 157-163.	0.4	23
9	Correlation of Currently Used Radiobiological Parameters with Local Control and Acute and Late Mucosal Toxicity in Randomised Studies of Altered Fractionation for Locally Advanced Head and Neck Cancer. Clinical Oncology, 2011, 23, 29-33.	0.6	20
10	Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial. Oral Oncology, 2021, 113, 105112.	0.8	16
11	Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. Cancers, 2021, 13, 1413.	1.7	13
12	Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer. Radiotherapy and Oncology, 2009, 93, 654.	0.3	11
13	Does Dose to an Oral Mucosa Organ at Risk Predict the Duration of Grade 3 Mucositis after Intensity-modulated Radiotherapy for Oropharyngeal Cancer?. Clinical Oncology, 2016, 28, e216-e219.	0.6	9
14	Models of acute mucosal tolerance to radiotherapy alone applied to synchronous chemoradiation schedules in head and neck cancer. Tumor Biology, 2014, 35, 2017-2023.	0.8	7
15	Revised radiobiological modelling of the contribution of synchronous chemotherapy to the rate of grades 3â€“4 mucositis in head and neck cancer. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 733-738.	0.9	5
16	To the Editor. Radiotherapy and Oncology, 2003, 68, 89-90.	0.3	4
17	A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic. Clinical and Translational Radiation Oncology, 2021, 30, 50-59.	0.9	4
18	Gap compensation during accelerated hypofractionated radiotherapy in head and neck cancer. Journal of Radiotherapy in Practice, 2008, 7, 31-38.	0.2	3

#	Article	IF	Citations
19	Modeling the Contribution of Synchronous Chemotherapy to the Rate of Grade 3 and 4 Mucositis in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2009, 75, 315.	0.4	3
20	Can Protons or Altered Fractionation Decrease Neurotoxicity after Chemoradiation in Head and Neck Cancer?. Clinical Oncology, 2014, 26, 762-764.	0.6	3
21	Dedifferentiated adenoid cystic carcinoma of the nasopharynx: a rare entity of head and neck cancer. BMJ Case Reports, 2016, 2016, bcr2016215889.	0.2	2
22	In Regard to Beitler etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 91, 455-456.	0.4	1
23	Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer. Medicines (Basel, Switzerland), 2018, 5, 65.	0.7	1
24	Delayed contrast and multiparametric MRI for treatment response assessment in brain metastases following stereotactic radiosurgery. Neuro-Oncology, 2021, 23, iv22-iv23.	0.6	1
25	Post-operative accelerated hypofractionated radiotherapy for adenoid cystic carcinoma. Journal of Radiotherapy in Practice, 2011, 10, 85-90.	0.2	0
26	Does radiosurgery have a role for patients with colorectal brain metastases?. Neuro-Oncology, 2018, 20, i25-i26.	0.6	0
27	Revised Modelling of the Addition of Synchronous Chemotherapy to Radiotherapy in Squamous Cell Carcinoma of the Head and Neckâ€"A Low Î±/Î²?. Medicines (Basel, Switzerland), 2018, 5, 54.	0.7	0
28	In reply to Iqbal et al.. Oral Oncology, 2021, 120, 105298.	0.8	0